

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Ifw
PATENT
Attorney Docket No.: 019934-003360US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On August 5, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]
Mark T. Davis



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BURNS et al.

Application No.: 10/698,541

Filed: October 30, 2003

For: COMPOSITIONS AND METHODS
FOR DETECTING AND TREATING
DISEASES AND CONDITIONS
RELATED TO CHEMOKINE
RECEPTORS

Examiner: Not yet assigned

Art Unit: 1646

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The reference cited on attached form PTO/SB/08A is being called to the attention of the Examiner. A copy of the reference is enclosed. It is respectfully requested that the cited reference be expressly considered during the prosecution of this application, and the reference be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination Report to the corresponding European Application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Matthew E. Hinsch
Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
MEH:mtd
60555335 v1



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			<i>Application Number</i>	10/698,541
			<i>Filing Date</i>	October 30, 2003
			<i>First Named Inventor</i>	Burns, Jennifer M.
			<i>Art Unit</i>	1646
			<i>Examiner Name</i>	Not yet assigned
Sheet	1	of 1	<i>Attorney Docket Number</i>	019934-003360US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	EBERT, Lisa M. et al.; "Coregulation of CXC Chemokine Receptor and CD4 Expression on T Lymphocytes During Allogeneic Activation"; 2001, <u>Journal of Immunology</u> , Vol. 166, No. 8, pp. 4870-4878.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.